Viking Therapeutics, Inc.
VKTX
$33.20
-$1.22-3.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.52M | 53.39M | 49.28M | 42.81M | 37.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.84M | 172.32M | 150.92M | 133.97M | 124.68M |
| Operating Income | -212.84M | -172.32M | -150.92M | -133.97M | -124.68M |
| Income Before Tax | -171.55M | -128.24M | -109.96M | -99.15M | -96.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -171.55 | -128.24 | -109.96 | -99.15 | -96.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.55M | -128.24M | -109.96M | -99.15M | -96.75M |
| EBIT | -212.84M | -172.32M | -150.92M | -133.97M | -124.68M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.53 | -1.15 | -1.01 | -0.94 | -0.94 |
| Normalized Basic EPS | -0.96 | -0.72 | -0.63 | -0.59 | -0.59 |
| EPS Diluted | -1.53 | -1.15 | -1.01 | -0.94 | -0.94 |
| Normalized Diluted EPS | -0.96 | -0.72 | -0.63 | -0.59 | -0.59 |
| Average Basic Shares Outstanding | 446.46M | 444.71M | 436.10M | 424.70M | 413.64M |
| Average Diluted Shares Outstanding | 446.46M | 444.71M | 436.10M | 424.70M | 413.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |